Use of liposomal formulations for controlled delivery of antineoplastic drugs
DOI:
https://doi.org/10.33448/rsd-v9i11.8511Keywords:
Liposomes; Nanoparticles; Antineoplastic.Abstract
In the pharmacological treatment of cancer, drugs with advanced therapeutic performance based on nanotechnologies have shown better performance compared to traditional drugs and among these, liposomal nanocarriers are more effective in directing these therapies to cancer cells, as they are able to make drugs available directly on the affected organs, tissues and cells, providing selectivity and less toxicity. The aim of this study was to evaluate the advantages of using liposomal nanocarriers in drugs used for antineoplastic therapy. This is a review of the literature, carried out by searching for scientific articles in the electronic databases Pubmed, Scielo and Google Scholar, using the terms "liposomes", "nanocarreaes" and "antineoplastic therapy" as descriptors, with a time frame of 2015 to 2020. The results suggest that the use of liposomal nanocarriers applied to drugs for antineoplastic therapy has shown to be a promising technology for its selectivity, non-toxicity, biocompatibility, in addition to being blood-stable, non-immunogenic and biodegradable. However, it is necessary to seek advances in the optimization of its use and its standardization, aiming at greater safety in its use in an attempt to align the innovations in this area with clinical practice.
References
Alavi, M., & Hamidi, M. (2019). Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab Pers Ther. 34(1).
Aryasomayajula, B., Salzano, G., & Torchilin, V. P. (2017). Multifunctional Liposomes. Methods Mol Biol. 1530:41-61.
Bahrami, B., Hojjat-Farsangi, M., Mohammadi, H., Anvari, E., Ghalamfarsa, G., Yousefi, M., & Jadidi-Niaragh, F. (2017). Nanoparticles and targeted drug delivery in cancer therapy, Immunology Letters, Volume 190, Pages 64-83, ISSN 0165-2478.
Bozzuto, G., & Molinari, A. (2015). Liposomes as nanomedical devices. Int J Nanomedicine. 10, 975-999.
Deshantri, A. K., Moreira, A. V., Ecker, V., Mandhane, S. N., Schiffelers, R. M., Buchner, M., & Fens, M. H. A. M. (2018). Nanomedicines for the treatment of hematological malignancies. J Control Release. 287, 194-215.
Huang, Z., Fu, J., & Zhang, Y. (2017). Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects. J Med Chem. 60 (18), 7617-7635.
Jain, A., & Jain, S. K. (2018b). Advances in Tumor Targeted Liposomes. Curr Mol Med. 18 (1), 44-57.
Jain, A., & Jain, S. K. (2018a). Stimuli-responsive Smart Liposomes in Cancer Targeting. Curr Drug Targets. 19(3), 259-270.
Khan, A. A., Allemailem, K. S., Almatroodi, S. A., Almatroudi, A., & Rahmani, A. H. (2020). Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications. 3 Biotech. 10(4):163.
Kopeckova, K., Eckschlager, T., Sirc, J., Hobzova, R., Plch, J., Hrabeta, J., & Michalek, J. (2019). Nanodrugs used in cancer therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 163(2), 122-131.
Lee, Y., & Thompson, D. H. (2017). Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 9(5), 10.1002/wnan.1450.
Li. Z., Di, C., Li, S., Yang, X., & Nie, G. (2019). Smart Nanotherapeutic Targeting of Tumor Vasculature. Acc Chem Res; 52 (9), 2703-2712.
Li, Z., Tan, S., Li, S., Shen, Q., & Wang, K. (2017). Cancer drug delivery in the nano era: An overview and perspectives (Review). Oncol Rep. 38 (2), 611-624.
Martins, M. de F. M. (2018). Estudos de Revisão de Literatura. Fiocruz (Rio de Janeiro), p. 02. Recuperado de: https://www.arca.fiocruz.br/bitstream/icict/29213/2/Estudos_revisao.pdf
Melo, R. L. F., Souza, I. C. da C., Carvalho, A. J. R., Bezerra, E. M., & Costa, R. F. da. (2020). As nanopartículas como ferramentas biológicas: uma revisão exploratória. Research, Society and Development, 9 (7).
Michel, T., Link, A., Abraham, M. K., Schlensak, C., Peter, K., Wendel, H. P., Wang, X., & Krajewski, S. (2019). Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA. J. Vis. Exp. (144).
Pérez-Herrero, E., & Fernández-Medarde, A. (2015). Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 93, 52-79.
Raj, R., Mongia, P., Sahu, S. K., & Ram, A. (2016). Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions. Curr Drug Targets. 17(2), 206-228.
Sayour, E. J., Mendez-Gomez, H. R., & Mitchell, D. A. (2018). Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes. Int J Mol Sci. 19 (10), 2890.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Gleysiane Gonçalves de Sousa; Izaura Maria Rocha; Deuzuíta dos Santos Freitas Viana
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
